Vancouver, British Columbia  - November  14,  2002  Forbes  Medi-Tech  Inc. (TSE:FMI  and NASDAQ:FMTI) today announced  that the results of its  latest designer cooking oil clinical trial will be presented at the American Heart Association's (AHA) Scientific  Sessions 2002 conference  in Chicago, IL on November 18, 2002. The clinical trial completed earlier this year at McGill University  was  shown  to help participants lose  weight  and lower  their cholesterol levels.

"This conference is  a good opportunity to  demonstrate the significance of Forbes'  designer cooking oil,"  said  Jerzy  Zawistowski,  Vice President, Functional Foods & Nutraceuticals, Forbes Medi-Tech  Inc. "Having  the  AHA accept the study abstract for presentation at this conference is a boost to
the  credibility  of   the  designer  oil  study  and  its  results",  said
Zawistowski.

In a clinical study announced in May  2002, 24 healthy men on  a controlled
diet   incorporating   Forbes'  "designer  oil"   showed   a  statistically
significant  decrease in total body  weight  tissue  in  28  days.    Study
participants who received  olive oil in their diet (control group) did  not
demonstrate   any  changes   in  body  compartment  volumes.  In  addition,
participants who consumed designer oil showed a  decrease  of  Low  Density Lipoprotein  (LDL) cholesterol concentrations. The Statistical results will be presented at the conference in Chicago.
 
About the American Heart Association
The American Heart Association is a national voluntary  health agency whose mission is to  reduce disability and death from cardiovascular diseases and stroke.  The American Heart Association and its affiliates support research activities broadly related to cardiovascular function and diseases, stroke, basic  science,  clinical,  bioengineering/biotechnology and  public health problems.  The American  Heart  Association's  Scientific Sessions  is  the world's  largest  convention for  scientists  and  healthcare professionals devoted to  the  science of cardiovascular disease  and stroke. Over 25,000 people attended the 2001 conference.

About Forbes Medi-Tech Inc.
Forbes Medi-Tech  Inc. is  a  biopharmaceutical company  dedicated  to  the research, development and  commercialization  of innovative pharmaceuticals
and   nutraceutical   products  for   the  prevention  and   treatment   of
cardiovascular and related  diseases. By extracting plant sterols from wood pulping by-products, Forbes has developed cholesterol-lowering agents to be used  as  pharmaceutical therapeutics, dietary  supplements and  functional food ingredients.

NASDAQ and  the Toronto Stock Exchange  have not reviewed and do not accept responsibility  for the adequacy or accuracy of  the  content of  this News Release.  This press release  contains  certain forward-looking  statements within the  meaning of  Section 27A of the U.S.  Securities Act and Section 21E of the U.S.  Securities Exchange  Act of 1934, which statements can  be identified by  the  use of forward-looking  terminology, such  as,  "will", "to",  "can"  or  comparable terminology  referring  to  future  events  or results.  The Company's actual  results could differ materially from  those anticipated  in these forward-looking statements as a  result  of  numerous factors,  including without  limitation,  research and  development  risks, including the fact that further research and clinical trials are needed for designer oil which may not proceed or if they do, may not duplicate results of previous trials or otherwise  demonstrate anticipated  results; the fact that presentations and conferences may not proceed as  currently scheduled;
and intellectual property risks.   See the Company's reports filed with the
Toronto Stock Exchange,  the B.C. and Ontario  Securities Commissions,  and the  U.S.  Securities  and  Exchange  Commission  from  time  to  time  for cautionary statements  identifying other important  factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results  referred to  in forward-looking  statements. The  Company assumes  no obligation  to update the information contained in this press release.